Time trends in the prescription of statins for the primary prevention of cardiovascular disease in the United Kingdom: A cohort study using The Health Improvement Network primary care data

Clinical Epidemiology

Volumn 8, Issue , 2016, Pages 123-132

  O’Keeffe, Aidan G ^a   Nazareth, Irwin ^a   Petersen, Irene ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

Cardiovascular disease; Primary prevention; Statin therapy; Time trend; United Kingdom

Indexed keywords

HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; CARDIOVASCULAR DISEASE; CHEMOPROPHYLAXIS; COHORT ANALYSIS; CONTROLLED STUDY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRESCRIPTION; PREVALENCE; PRIMARY MEDICAL CARE; PRIMARY PREVENTION; SEX DIFFERENCE; SOCIAL ISOLATION; TREND STUDY; UNITED KINGDOM;

EID: 84975267471     PISSN: None     EISSN: 11791349     Source Type: Journal    
DOI: 10.2147/CLEP.S104258     Document Type: Article

References (50)

1. Taylor F, Ward K, Moore TH, et al. Statins for the primary prevention of cardiovascular disease. Cochrane Database Syst Rev. 2013;1:CD004816.
2. Ebrahim S, Taylor FC, Brindle P. Statins for the primary prevention of cardiovascular disease. BMJ. 2014;348:g280.
3. Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet. 1994;344:1383-1389.
4. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. The antihypertensive and lipid-lowering treatment to prevent heart attack trial. Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs usual care: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT-LLT). JAMA. 2002;288:2998-3007.
5. Baigent, C, Keech A, Kearney PM, et al; Cholesterol Treatment Trialists' (CTT) Collaborators. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet. 2005;366:1267-1278.
6. Brugts JJ, Yetgin T, Hoeks SE, et al. The benefits of statins in people without established cardiovascular disease but with cardiovascular risk factors: meta-analysis of randomised controlled trials. BMJ. 2009;338:b2376.
7. Trusler D. Statin prescriptions in UK now total a million each week. BMJ. 2011;343:d4350.
8. NICE. Statins for the Prevention of Cardiovascular Events. London: NICE; 2006.
9. D'Agostino RB, Vasan RS, Pencina MJ, et al. General cardiovascular risk profile for use in primary care: the Framingham Heart Study. Circulation. 2008;117:743-753.
10. Hippisley-Cox J, Coupland C, Vinogradova Y, Robson J, May M, Brindle P. Derivation and validation of QRISK, a new cardiovascular disease risk score for the United Kingdom: prospective open cohort study. BMJ. 2007;335:136.
11. Hippisley-Cox J, Coupland C, Vinogradova Y, et al. Predicting cardiovascular risk in England and Wales: prospective derivation and validation of QRISK2. BMJ. 2008;336:1475-1482.
12. Collins GS, Altman DG. Predicting the 10 year risk of cardiovascular disease in the United Kingdom: independent and external validation of an updated version of QRISK2. BMJ. 2012;344:e4181.
13. DeWilde S, Carey IM, Bremner SA, Richards N, Hilton SR, Cook DG. Evolution of statin prescribing 1994-2001: a case of agism but not of sexism? Heart. 89;2003:417-421.
14. Wei L, Ebrahim S, Bartlett C, Davey PD, Sullivan FM, MacDonald TM. Statin use in the secondary prevention of coronary heart disease in primary care: cohort study and comparison of inclusion and outcome with patients in randomised trials. BMJ. 2005;330:821.
15. Carey IM, DeWilde S, Shah SM, Harris T, Whincup PH, Cook DG. Statin use after first myocardial infarction in UK men and women from 1997 to 2006: Who started and who continued treatment? Nutr Metab Cardiovasc Dis NMCD. 2012;22:400-408.
16. Ashworth M, Lloyd D, Smith RS, Wagner A, Rowlands G. Social deprivation and statin prescribing: a cross-sectional analysis using data from the new UK general practitioner 'Quality and Outcomes Framework'. J Public Health (Oxf). 2007;29:40-47.
17. Teeling M, Bennett K, Feely J. The influence of guidelines on the use of statins: analysis of prescribing trends 1998-2002. Br J Clin Pharmacol. 2005;59:227-232.
18. Walley T, Folino-Gallo P, Stephens P, Van Ganse E. Trends in prescribing and utilization of statins and other lipid lowering drugs across Europe 1997-2003. Br J Clin Pharmacol. 2005;60:543-551.
19. Bartholomeeusen S, Vandenbroucke JP, Truyers C, Buntinx F. Trends in total cholesterol screening and in prescribing lipid-lowering drugs in general practice in the period 1994-2003. BMC Fam Pract. 2008;9:39.
20. Geleedst-De Vooght M, Maitland-van der Zee AH, Schalekamp T, Mantel-Teeuwisse A, Jansen P. Statin prescribing in the elderly in the Netherlands: a pharmacy database time trend study. Drugs Aging. 2010;27:589-596.
21. Bijlsma MJ, Hak E, Bos JHJ, Berg LTW, de J den, Janssen, F. Inclusion of the birth cohort dimension improved description and explanation of trends in statin use. J Clin Epidemiol. 2012;65:1052-1060.
22. Wallach Kildemoes H, Vass M, Hendriksen C, Andersen M. Statin utilization according to indication and age: a Danish cohort study on changing prescribing and purchasing behaviour. Health Policy. 2012;108:216-227.
23. Upmeier E, Korhonen MJ, Helin-Salmivaara A, Huupponen R. Statin use among older Finns stratified according to cardiovascular risk. Eur J Clin Pharmacol. 2013;69:261-267.
24. Bijlsma MJ, Janssen F, Lub R. Birth cohort appeared to confound effect estimates of guideline changes on statin utilization. J Clin Epidemiol. 2015;68:334-340.
25. Neutel CI, Morrison H, Campbell NRC, de Groh M. Statin use in Canadians: trends, determinants and persistence. Can J Public Health. 2007;98:412-416.
26. Ma J, Sehgal NL, Ayanian JZ, Stafford RS. National trends in statin use by coronary heart disease risk category. PLoS Med. 2005;2:e123.
27. Johansen ME, Green LA, Sen A, Kircher S, Richardson CR. Cardiovascular risk and statin use in the United States. Ann Fam Med. 2014;12:215-223.
28. Cohen JD, Brinton EA, Ito MK, Jacobson TA. Understanding Statin Use in America and Gaps in Patient Education (USAGE): an internetbased survey of 10,138 current and former statin users. J Clin Lipidol. 2012;6:208-215.
29. Bourke A, Dattani H, Robinson M. Feasibility study and methodology to create a quality-evaluated database of primary care data. Inform Prim Care. 2004;12:171-177.
30. Blak BT, Thompson M, Dattani H, Bourke A. Generalisability of The Health Improvement Network (THIN) database: demographics, chronic disease prevalence and mortality rates. Inform Prim Care. 2011;19:251-255.
31. Chisholm, J. The Read clinical classification. BMJ. 1990;300:1092-1092.
32. Maguire A, Blak BT, Thompson M. The importance of defining periods of complete mortality reporting for research using automated data from primary care. Pharmacoepidemiol Drug Saf. 2009;18:76-83.
33. Horsfall L, Walters K, Petersen I. Identifying periods of acceptable computer usage in primary care research databases. Pharmacoepidemiol Drug Saf. 2013;22:64-69.
34. Man SL, Petersen I, Thompson M, Nazareth I. Antiepileptic drugs during pregnancy in primary care: a UK population based study. PLoS One. 2012;7:e52339.
35. Petersen I, McCrea RL, Osborn DJ, et al. Discontinuation of antipsychotic medication in pregnancy: a cohort study. Schizophr Res. 2014;159:218-225.
36. Marston L, Nazareth I, Petersen I, Walters K, Osborn DP. Prescribing of antipsychotics in UK primary care: a cohort study. BMJ Open. 2014;4:e006135.
37. Abramsom J. Prescribing statins: time to rein it in. Pharm J. 2015;294. doi:10.1211/PJ.2015.20068145.
38. Mihaylova B, Briggs A, Armitage J, Parish S, Gray A, Collins R; Heart Protection Study Collaborative. Lifetime cost effectiveness of simvastatin in a range of risk groups and age groups derived from a randomised trial of 20 536 people. BMJ. 2006;333:1145.
39. Lazar LD, Pletcher MJ, Coxson PG, Bibbins-Domingo K, Goldman L. Cost-effectiveness of statin therapy for primary prevention in a low-cost statin era. Circulation. 2011;124:146-153.
40. Mansi I, Frei CR, Pugh MJ, Makris U, Mortensen EM. Statins and musculoskeletal conditions, arthropathies, and injuries. JAMA Intern Med. 2013;173:1-10.
41. Mikus CR, Boyle LJ, Borengasser SJ, et al. Simvastatin impairs exercise training adaptations. J Am Coll Cardiol. 2013;62:709-714.
42. Zhang H, Plutzky J, Skentzos S, et al. Discontinuation of statins in routine care settings: a cohort study. Ann Intern Med. 2013;158:526-534.
43. Mosca L, Barrett-Connor E, Wenger NK. Sex/gender differences in cardiovascular disease prevention what a difference a decade makes. Circulation. 2011;124:2145-2154.
44. Kannel WB, McGee DL. Diabetes and cardiovascular disease. The Framingham study. JAMA. 1979;241:2035-2038.
45. Barrett-Connor E. Sex differences in coronary heart disease why are women so superior? The 1995 Ancel Keys Lecture. Circulation. 1997;95:252-264.
46. Wilson PWF, D'Agostino RB, Levy D, et al. Prediction of coronary heart disease using risk factor categories. Circulation. 1998;97:1837-1847.
47. O'Keeffe AG, Petersen I, Nazareth I. Initiation rates of statin therapy for the primary prevention of cardiovascular disease: an assessment of differences between countries of the UK and between regions within England. BMJ Open. 2015;5:e007207.
48. Wilmot KA, Khan A, Krishnan S, Eapen DJ, Sperling L. Statins in the elderly: A patient-focused approach. Clin Cardiol. 38, 56-61 (2015).
49. Lis Y, Mann RD. The VAMP Research multi-purpose database in the U.K. J Clin Epidemiol. 1995;48:431-443.
50. Abramson JD, Rosenberg HG, Jewell N, Wright JM. Should people at low risk of cardiovascular disease take a statin? BMJ. 2013;347:f6123.